DeVilbiss Healthcare Awarded Patent for SmartCode® Technology

SOMERSET, PA – April 10, 2014 – DeVilbiss Healthcare was recently awarded a patent* for its innovative SmartCode® Remote Therapy Monitoring system. The development of SmartCode technology revolutionized the way in which patients can remotely report CPAP therapy usage and efficacy data to the health provider. With this patent, DeVilbiss is now protected from other imitation codes on the market.

“We are pleased to have been awarded a U.S. patent, which recognizes the novelty and usefulness of our SmartCode technology,” said Allan Jones, Director of Research and Development at DeVilbiss. “The SmartCode feature is a simple, accurate and reliable way to communicate usage and therapy data. We are delighted to be able to exclusively offer this feature to our customers and users with every IntelliPAP device.”


SmartCode technology is an effective solution for data reporting that involves no modems, no wireless coverage gaps and no extra costs. It’s included as a standard feature with each of DeVilbiss Healthcare’s IntelliPAP CPAP devices. The IntelliPAP CPAP system has a failure rate of less than one percent, best-in-industry warranty and is proudly made in the USA**.


The SmartCode monitoring system allows summary therapy and device usage data to be compressed into onboard, encrypted codes that are displayed on the IntelliPAP display panel. Each character generated in the SmartCode information represents a data set.


To decipher the SmartCode information, the clinician or provider calls the patient to acquire specific codes from the IntelliPAP system. Once the clinician or provider has the desired code, he or she logs onto to enter the code into the SmartCode report generator.


The report generator creates a report that includes text and graphs. Patients can also view their own therapy data, including leaks, expiratory puffs, pressure plateau and non-responding events, and have the option print or save their reports. This engages the patient and can enhance the effectiveness of therapy.


“The first two weeks of therapy are the most critical in determining long-term CPAP adherence,” said Brian Palmer, Product Marketing Director – Sleep at DeVilbiss. “With the SmartCode system, healthcare providers can call the patient within the first few days of therapy, obtain the SmartCode data and generate a report to determine how the patient’s therapy is going and  address any concerns.”


* U.S. patent 8649510
**Made in the USA of US and imported parts

» Continue to US website

DeVilbiss Healthcare

Thank you for visiting DeVilbiss Healthcare. Please note that all information contained on this website including, but not limited to, warranties, product specifications and model availability is specific to products offered to North American customers only. To learn more about DeVilbiss products that are sold internationally, please visit one of these websites:

DeVilbiss Healthcare does not sell directly to consumers. Please go to to locate a DeVilbiss provider near you.